Supply of opioids predicts long-term use in injured workers

(HealthDay)—The number of days supplied of an initial opioid prescription is the strongest risk factor for developing long-term opioid use among previously opioid-free injured workers, according to a study published online July 17 in JAMA Network Open. Zoe Durand, Ph.D., from the Tennessee Department of Health in Nashville, and colleagues examined the prevalence and risk factors of long-term opioid use […]

Continue reading »

Dupixent approved for chronic rhinosinusitis with nasal polyps

Dupixent (dupilumab) has been approved to treat nasal polyps in adults with chronic rhinosinusitis, the U.S. Food and Drug Administration announced today. Dupixent, which is administered through injection, was previously approved to treat eczema in patients 12 years and older and as an add-on maintenance treatment for moderate-to-severe eosinophilic asthma or oral corticosteroid-dependent asthma. The recommended dose for adult patients […]

Continue reading »

Growing life expectancy inequality in US cannot be blamed on opioids alone

A new University of Michigan study challenges a popularized view about what’s causing the growing gap between the lifespans of more- and less-educated Americans—finding shortcomings in the widespread narrative that the United States is facing an epidemic of “despair.” Some influential studies have argued that growing life expectancy inequality is driven by so-called “deaths of despair,” suggesting that economic stagnation […]

Continue reading »

Israeli drugmaker Teva to pay Oklahoma $85 mn in opioid suit

Israeli pharmaceutical giant Teva agreed on Sunday to pay the US state of Oklahoma $85 million to settle a lawsuit accusing it of fueling the state’s opioid epidemic, Oklahoma’s attorney general said. The announcement comes after Purdue Pharma, maker of the opioid painkiller OxyContin—a key driver of the crisis responsible for tens of thousands of deaths in the United States—reached […]

Continue reading »

Americans’ prescription med use is declining

(HealthDay)—Bucking a longstanding upward trend, new data shows that the percentage of Americans taking any prescription drug has fallen slightly over the past decade. Still, nearly half—45.8%— of Americans said they took at least one prescription medicine over the past month, according to a national survey conducted in 2015-2016. That’s a slight dip from the 48.3% of Americans —children and […]

Continue reading »

Australian doctors overprescribing flu antivirals

Australian doctors are prescribing antivirals for people with the flu who may not benefit, putting patients at risk of unnecessary side effects and potentially increasing the risk of antimicrobial resistance to these medications, researchers from the University of Adelaide have found. The large study, published in BMJ Open, investigated the prescription of antibiotics and antivirals for the management of influenza-like […]

Continue reading »

Lack of access to antibiotics is a major global health challenge

Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, it is less well known that many people in low- and middle-income countries continue to die because they lack access to antibiotics. The majority of the world’s annual 5.7 million antibiotic-treatable […]

Continue reading »

Advanced breast cancer drug combo approved for NHS in England

A new drug combo has been made available to some patients with advanced breast cancer on the NHS in England. The National Institute for Health and Care Excellence has recommended the drugs – called abemaciclib (Verzenio) and fulvestrant (Faslodex) – in new draft guidance, after the treatments were shown to slow disease progression and delay the need for chemotherapy in […]

Continue reading »

Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis

DUBLIN, March 12, 2019 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2b/3 study of TD-1473 in patients with moderately to severely active ulcerative colitis. TD-1473 is a novel, orally administered and gut-selective pan-Janus kinase (JAK) inhibitor in clinical development as a treatment for multiple inflammatory […]

Continue reading »
1 2